NorthWest Biotherapeutics Inc (NWBO)

[Baxers]

Many things that the CHM discuss are confidential. There is absolutely nothing whatsoever to suggest that this clinical trial discussion was about DCVax. It literally could be about thousands of other treatments. This CHM meeting alone discussed 39 specific medicines/ treatments, one clinical trial and a broader strategy about biosimilars.

To reiterate, this discussion was about a clinical trial and NOT about a marketing authorisation assessment. While there is certainly a chance that NWBO have submitted an IND to the MHRA for a forthcoming DCVax-L/ Direct clinical trial, there is literally zero to indicate that this discussion was about that.